Aegerion’s patent estate is a valuable asset to us and our shareholders. Patents and trademarks are central to the long-term success of biopharmaceutical products and our policy is to aggressively pursue intellectual property protection for all our products.
Aegerion owns patents as well as pending applications relating to compounds active at the inhibition of microsomal triglyceride transfer protein (MTP) that affect the production of cholesterol and triglycerides in both the liver and intestine. Our investigational product candidate lomitapide represents a potential first-in-class, oral, once-a-day treatment for a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.
Our patent estate includes US and international filings that comprise both granted patents and applications for key properties of the compound. These include:
- basic pharmaceutical composition of matter patents
- method of use to treat numerous diseases
- method of treatment
- commercial-scale manufacturing of MTP-I small molecules